Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
Rocamora V, Crespi L, Ferran M, Llamas-Velasco M, Del Alcázar E, Carrascosa JM, Beltran E, Urruticoechea-Arana A, Estebaranz JLL, Vidal D, Riera J, Rodríguez L, Armesto S, Fernández JM, Aparicio G, Pérez S, Porcar S, Montesinos E, Gallardo F. Rocamora V, et al. Among authors: ferran m. Dermatol Ther. 2022 Nov;35(11):e15865. doi: 10.1111/dth.15865. Epub 2022 Oct 9. Dermatol Ther. 2022. PMID: 36175141
[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M, Dilmé E, Puig L, Bordas X, Carrascosa JM, Ferran M, Herranz P, García-Bustinduy M, López Estebaranz JL, Alsina M, Rodríguez MA, Ribera M, Fernández-López E, Moreno JC, Belinchón Romero I, Vidal D; Grupo Español de Psoriasis de la Academia Española. Sánchez-Regaña M, et al. Among authors: ferran m. Actas Dermosifiliogr. 2010 Mar;101(2):156-63. Actas Dermosifiliogr. 2010. PMID: 20223158 Spanish.
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, Fonseca E, Carretero G, Daudén E, Marrón SE, López-Estebaranz JL, Ferrán M, Sánchez-Regaña M, Muñoz-Santos C, Belinchón I, Puig L; Grupo Español de Psoriasis. Morell L, et al. Among authors: ferran m. Actas Dermosifiliogr. 2011 Jun;102(5):354-64. doi: 10.1016/j.ad.2010.12.013. Epub 2011 Apr 29. Actas Dermosifiliogr. 2011. PMID: 21530928 Free article. Spanish.
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: ferran m. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, De la Cueva Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Peral F, Torrado R, Rivera R, Jiménez-Puya R, Mendiola MV, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. Among authors: ferran m. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):907-14. doi: 10.1111/jdv.12208. Epub 2013 Jul 15. J Eur Acad Dermatol Venereol. 2014. PMID: 23848131
Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, Ferran M, Sánchez-Regaña M, Collgros H, Bordas X, Notario J, Alsina M, Gil I, Izquierdo N, Aparicio G, Mollet J, Garcia-Patos V, Pujol RM. Martin-Ezquerra G, et al. Among authors: ferran m. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):56-60. doi: 10.1111/jdv.12438. Epub 2014 Mar 13. J Eur Acad Dermatol Venereol. 2015. PMID: 24629001
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, De-la-Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, Alsina M, Sánchez-Carazo JL, Ferrán M, Lopez-Estebaranz JL, Pérez-Zafrilla B, Llamas M, Rivera R, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. Among authors: ferran m. Actas Dermosifiliogr. 2015 Oct;106(8):638-43. doi: 10.1016/j.ad.2015.04.013. Epub 2015 Jun 30. Actas Dermosifiliogr. 2015. PMID: 26141003 Free article. English, Spanish.
Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchón-Romero I, Carrascosa JM, Ferrán M, Vanaclocha F, Herrera-Ceballos E, García-Doval I; Biobadaderm Study Group. Ruiz-Genao D, et al. Among authors: ferran m. Br J Dermatol. 2017 Mar;176(3):797-799. doi: 10.1111/bjd.14690. Epub 2016 Oct 17. Br J Dermatol. 2017. PMID: 27120993 No abstract available.
127 results